ARCHIVES

Long-term Hormonal Therapy Adds No Additional Benefits

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

November 1, 1985

The Cancer Letter Obtains “Confidential” Documents From Duke IRB Investigation

May 14, 2010

Nursing Center Moves Onto Campus

May 9, 1986

CTAC Discussion, Group Chairs Comment

December 17, 2010

HHS: Gallo Committed Scientific Misconduct In AIDS Virus Discovery

January 8, 1993